
## **Claudia Geue**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8255056/publications.pdf Version: 2024-02-01



CLAUDIA GELIE

#	Article	IF	CITATIONS
1	Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019, 380, 425-436.	27.0	548
2	Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the Rheumatic Diseases, 2020, 79, 771-777.	0.9	99
3	SPOILT FOR CHOICE: IMPLICATIONS OF USING ALTERNATIVE METHODS OF COSTING HOSPITAL EPISODE STATISTICS. Health Economics (United Kingdom), 2012, 21, 1201-1216.	1.7	39
4	Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. BMC Medicine, 2021, 19, 46.	5.5	39
5	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 2014, 15, 885-896.	2.8	38
6	Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques. PLoS ONE, 2015, 10, e0145022.	2.5	32
7	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-92.	2.8	27
8	A framework for conducting economic evaluations alongside natural experiments. Social Science and Medicine, 2019, 220, 353-361.	3.8	19
9	What is the impact of large-scale implementation of stroke Early Supported Discharge? A mixed methods realist evaluation study protocol. Implementation Science, 2019, 14, 61.	6.9	14
10	A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. BMJ Open, 2020, 10, e028575.	1.9	13
11	Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?. PLoS ONE, 2015, 10, e0119035.	2.5	12
12	Geographic variation of inpatient care costs at the end of life. Age and Ageing, 2016, 45, 376-381.	1.6	11
13	The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts. Palliative Medicine, 2018, 32, 1133-1141.	3.1	11
14	Large-scale implementation of stroke early supported discharge: the WISE realist mixed-methods study. Health Services and Delivery Research, 2021, 9, 1-150.	1.4	10
15	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 2019, 4, 108.	1.8	9
16	The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. PLoS ONE, 2016, 11, e0162980.	2.5	8
17	Scottish Keep Well health check programme: an interrupted time series analysis. Journal of Epidemiology and Community Health, 2016, 70, 924-929.	3.7	6
18	Cost impact of introducing a treatment escalation/limitation plan during patients' last hospital admission before death. International Journal for Quality in Health Care, 2020, 32, 694-700.	1.8	5

CLAUDIA GEUE

#	Article	IF	CITATIONS
19	The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information–Diabetes Collaboration. Diabetic Medicine, 2020, 37, 1927-1934.	2.3	4
20	Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population. PLoS ONE, 2022, 17, e0262293.	2.5	4
21	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	1.8	3
22	Towards transforming community eye care: an observational study and time-series analysis of optometrists' prescribing for eye disorders. Public Health, 2021, 196, 107-113.	2.9	2
23	Effect of individual-level and socioeconomic factors on long-term survival after cataract surgery over a 30-year period. Journal of Cataract and Refractive Surgery, 2017, 43, 537-542.	1.5	1
24	POS0530â€HOW DOES MULTIMORBIDITY IMPACT ON THE DIRECT AND INDIRECT COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS?. Annals of the Rheumatic Diseases, 2021, 80, 498.3-499.	0.9	1
25	Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide. PharmacoEconomics - Open, 2022, 6, 303-313.	1.8	1
26	PTH-104â€Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011. Gut, 2016, 65, A270.1-A270.	12.1	0
27	Cost-effectiveness of treating hepatitis C in Seychelles. Pan African Medical Journal, 2019, 33, 26.	0.8	0